Zai Lab Ltd (ZLAB) research
Zai Lab Ltd- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $24.33
- As of
Zai Lab Ltd (ZLAB): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-06.
As of . Source: SEC EDGAR filings for ZLAB. Method and limitations.
Share the ZLAB intelligence card
See the full ZLAB dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ZLAB on one page. Preview it with sample data, then open it live with a free account.
Preview the ZLAB dossierActive signals for ZLAB
- highCONSENSUS_BUY
3 tracked funds increased ZLAB this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +2669% to ZLAB (2026Q2)
- highINSTITUTIONAL_SURGE
D. E. Shaw & Co., Inc. added +123% to ZLAB (2026Q2)
- highINSTITUTIONAL_SURGE
TWO SIGMA INVESTMENTS, LP added +320% to ZLAB (2026Q2)
- mediumEARNINGS_MISS
Q2-2026: Missed consensus by 599.1%, EPS $-0.46 vs $-0.0658 estimate
FREE, NO ACCOUNT
Every signal on ZLAB, as it fires
You are seeing 5 of 12 signals recorded on ZLAB since 2026-05-31.
The five above landed across 3 days. The other 7 were recorded on 2 other days. 7 of the 12 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in ZLAB (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| TWO SIGMA INVESTMENTS, LPCUSIP 98887Q104 · 2026Q2 | $24.7M | 0.02% | , |
| CITADEL ADVISORS LLCCUSIP 98887Q104 · 2026Q2 | $24.4M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 98887Q104 · 2026Q2 | $2.7M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ZLAB
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
ZLAB against its peers
ZLAB's operating margin of -50.2% ranks in the 78th percentile of 15 Biotechnology sub-industry peers, fiscal periods ending between 2025-11-30 and 2025-12-31.
| Metric | ZLAB | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 457M USD | 27.8M USD | 85 | 16 |
| Operating margin | -50.2% | -1002.9% | 78 | 15 |
| Net margin | -38.4% | -905.7% | 78 | 15 |
| Return on equity | -24.5% | -35.7% | 62 | 24 |
Peers (24): NAMS, PGEN, MBX, DYN, ATAI, QURE, RCUS, CLDX, BEAM, IRON, DNLI, ELVN, GRTX, IMNM, NRIX, ARQT, SLS, ACAD, VERA, XENE, VRDN, ADMA, MLYS, IDYA. Left out: ZLDPF (no annual filing). Fiscal periods ending between 2025-11-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (ZLAB: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more ZLAB signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to ZLABand get the insider, 13F, options, and confluence read in one view.